Tucidinostat

Phase 3Small molecule

CChipscreen Biosciences, Ltd.

Tucidinostat is one of 177 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

176

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

5 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Colorectal Cancer

NCT06497985

Q4 2032

Phase 3Recruiting

Lymphoma

NCT06947967

Clinical

Trials by Indication[1]

Breast Cancer5 trials

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Unknown status·HHunan Cancer Hospital·Phase 2·NCT05633914·90 enrolled

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Completed·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT04465097·30 enrolled

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Unknown status·Wwang shusen·Phase 2·NCT05411380·73 enrolled

Show 2 more trials

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Unknown status·—··NCT05276713·50 enrolled

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Unknown status·GGuangdong Women and Children Hospital·Phase 2·NCT04999540·73 enrolled

First-line Treatment1 trial

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Active, not recruiting·CChipscreen Biosciences, Ltd.·Phase 2·NCT05519865·118 enrolled

Triple-Negative Breast Cancer1 trial

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Unknown status·Wwang shusen·Phase 2·NCT05390476·126 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Completed·OOu Bai, MD/PHD·Phase 2·NCT04661943·30 enrolled

Colorectal Cancer1 trial

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT06497985·430 enrolled

3 more indications

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

Lymphoma1 trial

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT06947967·224 enrolled

Newly Diagnosed1 trial

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Active, not recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT04231448·423 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Tucidinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tucidinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tucidinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chipscreen Biosciences, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChipscreen Biosciences, Ltd.

Tucidinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2032

Trials by Indication[1]

Breast Cancer5 trials

First-line Treatment1 trial

Triple-Negative Breast Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Colorectal Cancer1 trial

PTCL1 trial

Lymphoma1 trial

Newly Diagnosed1 trial

References

Drug Info

Quick Facts

Related News